INTEGRIS Cancer Institute Proton Campus

Oklahoma City, Oklahoma 73142

Use our guide to learn which trials are right for you!

We've found
1 trials
at this facility
MPN (Myeloproliferative Neoplasms) Clinical Trial
Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272)
Status: Enrolling, Phase II
Updated: 12/31/1969
INTEGRIS Cancer Institute Proton Campus
mi
from
Oklahoma City, OK
Click here to add this to my saved trials